Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: billkirn who wrote (5725)	12/3/1998 8:47:00 AM
From: John F Beule	Read Replies (2) \| Respond to of 6136

Early detection = early treatment, news should be good for the likes of AGPH: Calypte Biomedical Corp. (CALY): A new study found that a urine test made by the maker of screening tests can detect exposure to HIV in patients who failed to show exposure to the AIDS virus when their blood was tested. The results could help the company in its bid to persuade the U.S. Food and Drug Administration to let it market the product to screen blood donors who make the 25 to 30 million blood donations collected each year in the U.S. Calypte remained unchanged at 2 1/4. John

To: billkirn who wrote (5725)	12/9/1998 11:52:00 PM
From: JOHN W.	Read Replies (3) \| Respond to of 6136

So what has been going on for the last couple of weeks as this stock has been on fire? Well we got another much more violent week ahead as the shareholders meeting is 12/16/98. How much farther can we go in the next 7 days? Don't know. WHAT I DO KNOW IS THAT THE SHORTS DON'T WANT TO BE IN THIS STOCKS WHEN IT SPINS OFF. SHORTS DO NOT WANT TO BE IN THIS STOCK AS THIS MEETING APPROACHES NEXT WEEK AND BE SURPRISED AS AGPH REALIZES THAT IT WILL TAKE CRITICAL MASS R&D FOR THE FUTURE AND IS BOUGHT BY DD OR ANNOUNCES A LARGE MARKETING DEAL WITH TO TAKE ADVANTAGE OF THE SUSTIVA-VIRACEPT SYNERGY. I am not trying to spread a rumor. I said on the SI board before any analyst popped in was that I heard that AGPH was looking at this possibility of a deal with DuPont back in May. Yes, well before this stock plunge to 20. Before Fortune magazine discussed how DD was discussing a acquisition of MTC and AGPH, before 5 analyst discussed the probable acquisition of AGPH, before CNBC said that AGPH was looking to be bought out. Yeah REMUNE will be a bigger drug in one year than nelfinavir. Yes, the shear announcement that the cure for the common cold has entered clinical trial (next 2-3 weeks) will receive enough attention to drive this stock to the mid-60s. Does not matter, DD sold Conoco to turn their company a Life Sciences company. Several articles have alluded that DD has been interested in Agouron. Remember, next week when Agouron and DD announce the merger and the stock is between 75-90, you heard it here first.